Mankind Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/11/2025 ,inter alia, to consider and approve the unaudited standalone and ....
MANKIND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Mankind Pharma has informed BSE that its Board of Directors will meet on Thursday, November 6, 2025, to consider and approve the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (Q2 and H1 of FY26). The company has also confirmed that the trading window for dealing in its securities will remain closed until November 8, 2025, in line with insider trading regulations. This is a routine procedural disclosure ahead of the earnings announcement. No actual financial numbers or results have been disclosed in this filing.
This is a standard pre-earnings intimation and carries no direct impact on the stock. Investors should watch for the actual Q2/H1 FY26 results on or shortly after November 6, 2025 for any meaningful impact on the stock price.